Lansoprazole, H. pylori, and atrophic gastritis.
Kuipers
E J
EJ
Klinkenberg-Knol
E C
EC
Festen
H P
HP
Meuwissen
S G
SG
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology*; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives*; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole